Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy by Yanmeng Wang, Niels Vandewalle, Kim De Veirman, Karin Vanderkerken, Eline Menu, Elke De Bruyne

Get full text

Fueling CARs: metabolic strategies to enhance CAR T-cell therapy by Arne Van der Vreken, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Karine Breckpot, Eline Menu

Get full text

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma by Inge Oudaert, Arne Van der Vreken, Anke Maes, Elke De Bruyne, Kim De Veirman, Karin Vanderkerken, Eline Menu

Get full text

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity? by Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne

Get full text

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response by Eva De Smedt, Hui Lui, Hui Lui, Ken Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne

Get full text

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects by Lien De Beck, Sarah Melhaoui, Kim De Veirman, Eline Menu, Elke De Bruyne, Karin Vanderkerken, Karine Breckpot, Ken Maes

Get full text

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers by Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman

Get full text

AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies by Niels Vandewalle, Nathan De Beule, Ann De Becker, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Karine Breckpot, Nick Devoogdt, Kim De Veirman

Get full text

S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma by Yanmeng Wang, Catharina Muylaert, Arne Wyns, Philip Vlummens, Kim De Veirman, Karin Vanderkerken, Esther Zaal, Celia Berkers, Jérome Moreaux, Elke De Bruyne, Eline Menu

Get full text

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition by Mérédis Favreau, Koen Venken, Sylvia Faict, Ken Maes, Kim De Veirman, Elke De Bruyne, Xavier Leleu, Louis Boon, Dirk Elewaut, Karin Vanderkerken, Eline Menu

Get full text

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. by Song Xu, Gaia Cecilia Santini, Kim De Veirman, Isabelle Vande Broek, Xavier Leleu, Ann De Becker, Ben Van Camp, Karin Vanderkerken, Ivan Van Riet

Get full text

Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma by Fengjuan Jiang, Hui Liu, Fengping Peng, Zhaoyun Liu, Kai Ding, Jia Song, Lijuan Li, Jin Chen, Qing Shao, Siyang Yan, Kim De Veirman, Karin Vanderkerken, Rong Fu

Get full text

A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages by Emma Verheye, Daliya Kancheva, Hatice Satilmis, Niels Vandewalle, Rong Fan, Pauline M. R. Bardet, Emile J. Clappaert, Kevin Verstaen, Ann De Becker, Karin Vanderkerken, Kim De Veirman, Damya Laoui

Get full text

Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case... by Heleen Hanssens, Heleen Hanssens, Heleen Hanssens, Fien Meeus, Yannick De Vlaeminck, Quentin Lecocq, Janik Puttemans, Pieterjan Debie, Timo W. M. De Groof, Cleo Goyvaerts, Kim De Veirman, Karine Breckpot, Nick Devoogdt

Get full text

Radiotheranostic Agents in Hematological Malignancies by Jo Caers, Jo Caers, Elodie Duray, Elodie Duray, Louise Vrancken, Louise Vrancken, Guillaume Marcion, Valentina Bocuzzi, Kim De Veirman, Ahmet Krasniqi, Margaux Lejeune, Nadia Withofs, Nick Devoogdt, Mireille Dumoulin, Amelie Eriksson Karlström, Matthias D’Huyvetter

Get full text

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach by Philip Vlummens, Philip Vlummens, Stefaan Verhulst, Kim De Veirman, Anke Maes, Eline Menu, Jérome Moreaux, Jérome Moreaux, Jérome Moreaux, Hugues De Boussac, Nicolas Robert, Elke De Bruyne, Dirk Hose, Fritz Offner, Karin Vanderkerken, Ken Maes, Ken Maes

Get full text

Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia by Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Elke De Bruyne, Eline Menu, Nathan De Beule, Ann De Becker, Gamze Ates, Ann Massie, Tessa Kerre, Marie Törngren, Helena Eriksson, Karin Vanderkerken, Karine Breckpot, Ken Maes, Kim De Veirman

Get full text

ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation by Dan Zhang, Kim De Veirman, Rong Fan, Qiang Jian, Yuchen Zhang, Li Lei, Holly Evans, Yanmeng Wang, Lei Lei, Baiyan Wang, Ramone A. Williamson, Andrew Chantry, Pengcheng He, Ang Li, Hendrik De Raeve, Karin Vanderkerken, Aili He, Jinsong Hu

Get full text

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma by Marie Törngren, Rong Fan, Eline Menu, Helena Eriksson, Karin Vanderkerken, Andrew Chantry, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Holly Evans, Nathan De Beule, Dirk Hose, Ken Maes, Karine Breckpot, Kim De Veirman

Get full text

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma by Martina Emde-Rajaratnam, Susanne Beck, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose

Get full text